Uni-Bio Science Group Limited — Earnings Release 2021

Aug 9, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [25 x 24] intentionally omitted <==

==> picture [31 x 35] intentionally omitted <==

==> picture [24 x 28] intentionally omitted <==

==> picture [117 x 50] intentionally omitted <==

UNI-BIO SCIENCE GROUP LIMITED 聯康生物科技集團有限公司[*]

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “ Board ”) of directors (the “ Directors ”) of Uni-Bio Science Group Limited (the “ Company ”, together with its subsidiaries, the “ Group ”) pursuant to 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”) and Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the information currently available to the Board, which includes, but without limitation to, the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021, the Directors wish to inform the shareholders (the “ Shareholders ”) and potential investors of the Company that a net profit of the Group for the six months ended 30 June 2021 is expected to be recorded, as compared with a net loss of the Group for the six months ended 30 June 2020.

The Board considers that the net profit for the six months ended 30 June 2021 is mainly attributable to the (i) increase in revenue and gross profit of the Group for the six months ended 30 June 2021 of more than 130% and 110% respectively as compared with the six months ended 30 June 2020, and (ii) the sales orders have rebounded from the impact of the COVID-19 epidemic since the second half of 2020, and continued through the first half of 2021.

As the Company is still in the process of finalising the results for the six months ended 30 June 2021, the information contained in this announcement is based on the management’s preliminary review on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 and current information available to the Board and has not been reviewed by the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2021 which is expected to be published by the end of August 2021.

* For identification purpose only

– 1 –

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board Uni-Bio Science Group Limited Kingsley Leung Chairman

Hong Kong, 9 August 2021

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

– 2 –